Vivere Oncotherapies: Valuation, Funding & Investors
Vivere Oncotherapies is a UC Berkeley spin-out developing cancer therapies that activate the immune system to detect and destroy cancer cells in immunologically cold tumors. The company leverages a proprietary bioengineering platform to design targeted immunotherapies that reach tumors more efficiently and provide treatments for difficult-to-treat solid tumors such as colorectal and ovarian cancers.
Leadership & Board
- Current Number of Employees
- 11
- Current LinkedIn Followers
- 1,120
Latest Estimated Valuation
- Total Amount Raised
- $10M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $10M
- Latest Funding Round
- Investment
Employee Trend
Vivere Oncotherapies had 11 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Vivere Oncotherapies had 1,120 followers as of November 16, 2026. The number of followers increased by 2 (0.18%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 13, 2026 | Investment | $10.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Freeflow Ventures | Investment |
| YK Bioventures | Investment |
| Berkeley Frontier Fund | Investment |
| Pillar | Investment |
| National Cancer Institute | Investment |
Similar Companies
A snapshot of private companies similar to Vivere Oncotherapies, helping you discover and navigate related company profiles.
Related News and Analysis







